Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 312

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 19
Chunk 312
---
.

During the years ended December 31,
2022, and December 31, 2023, a total of1,556,817and9,984of such warrants were exercised into1,160,016and324ordinary shares of
the Company, respectively.

On September 16, 2024, the remaining2,313,976Warrants expired unexercised.

F-23

ALPHA TAU MEDICAL
LTD. AND ITS SUBSIDIARIES

NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS

U. S. dollars
in thousands (except share and per share data)

NOTE 11:- COMMITMENTS AND CONTINGENT LIABILITIES

  A guarantee in the amount of $ 3,255 was issued by a bank to secure rent payments.  

  The Company has received royalty-bearing grants from the IIA to finance                                                                   
  its research and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount    
  of $ 5,445 through December 31, 2024. If income is generated from a funded research program, the Company is committed to pay royalties    
  at a rate of 3% of future revenue arising from such research program(s), and up to a maximum of 100% of the amount received, linked to    
  the U. S. dollar (for grants received under programs approved until December 31, 2023, the maximum to be repaid is 100% plus interest at  
  LIBOR, and from January 1, 2024, the 12 month Term SOFR interest).                                                                        
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

In addition, under the intellectual
property purchase agreement with Althera, the Company assumed all of Althera’s liabilities towards the IIA totaling $474of royalty-bearing
grants received by Althera (plus accrued interest). The Company’s liability to the IIA at December 31, 2024, including royalty-bearing
grants received by the Company, grants assumed from Althera and the associated interest accrued on all such grants, totaled $7,222.

  Under the February 2, 2016 intellectual property purchase agreement with Althera, the Company is obligated                               

  The Company also entered into intellectual property agreements with Ramot at Tel Aviv University Ltd.,                                        
  the technology transfer company of Tel Aviv University (“ Ram